• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

    2/10/22 4:08:18 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SQZ alert in real time by email
    SC 13G/A 1 tm226120d1_sc13ga.htm SCHEDULE 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    SQZ biotechnologies company

     

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    78472W 10 4
    (CUSIP Number)

     

    DECEMBER 31, 2021

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 78472W 10 4

     

    1. Name of Reporting Persons
    Nanodimension II, L.P.
     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ¨
     

    (b) ¨

     

    3.

    SEC Use Only

     

    4. Citizenship or Place of Organization

    Cayman Islands

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power

    1,445,221 
     
    6. Shared Voting Power

    0
     
     
    7. Sole Dispositive Power

    1,445,221
     
     
    8. Shared Dispositive Power

    0
     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    1,445,221  
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11.

    Percent of Class Represented by Amount in Row (9)

    5.1%1

    12. Type of Reporting Person (See Instructions)

    PN

     

     

     

    1 This percentage is calculated based upon 28,066,795 shares of the Issuer’s common stock outstanding as of November 3, 2021, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 10, 2021.

     

    Page 2 of 8

     

     

    CUSIP No. 78472W 10 4

     

    1. Name of Reporting Persons
    Nanodimension II Management Limited
     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ¨
     

    (b) ¨

     

    3.

    SEC Use Only

     

    4. Citizenship or Place of Organization

    Cayman Islands

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power

    1,445,2211 
     
    6. Shared Voting Power

    0
     
     
    7. Sole Dispositive Power

    1,445,2211 
     
    8. Shared Dispositive Power

    0
     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    1,445,2211  
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11.

    Percent of Class Represented by Amount in Row (9)

    5.1%2

     

    12. Type of Reporting Person (See Instructions)

    OO

     

     

     

    1 Consists of shares held by Nanodimension II, L.P.

     

    2 This percentage is calculated based upon 28,066,795 shares of the Issuer’s common stock outstanding as of November 3, 2021, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 10, 2021.

    Page 3 of 8

     

     

    CUSIP No. 78472W 10 4

     

    1. Name of Reporting Persons
    Jonathan Nicholson
     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ¨
     

    (b) ¨

     

    3.

    SEC Use Only

     

    4. Citizenship or Place of Organization

    Cayman Islands and United Kingdom

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power

    0 
     
    6. Shared Voting Power

    1,445,2211 
     
    7. Sole Dispositive Power

    0
     
     
    8. Shared Dispositive Power

    1,445,2211

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    1,445,2211  
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11.

    Percent of Class Represented by Amount in Row (9)

    5.1%2

     

    12. Type of Reporting Person (See Instructions)

    IN

     

     

     

    1 Consists of shares held by Nanodimension II, L.P.

     

    2 This percentage is calculated based upon 28,066,795 shares of the Issuer’s common stock outstanding as of November 3, 2021, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 10, 2021.

    Page 4 of 8

     

     

    CUSIP No. 78472W 10 4

     

    1. Name of Reporting Persons
    Richard Coles
     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ¨
     

    (b) ¨

     

    3.

    SEC Use Only

     

    4. Citizenship or Place of Organization

    Cayman Islands and United Kingdom

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power

    0 
     
    6. Shared Voting Power

    1,445,2211 
     
    7. Sole Dispositive Power

    0
     
     
    8. Shared Dispositive Power

    1,445,2211
     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    1,445,2211  
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    11. Percent of Class Represented by Amount in Row (9)

    5.1%2
    12. Type of Reporting Person (See Instructions)

    IN

     

     

     

    1 Consists of shares held by Nanodimension II, L.P.

     

    2 This percentage is calculated based upon 28,066,795 shares of the Issuer’s common stock outstanding as of November 3, 2021, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 10, 2021.

    Page 5 of 8

     

     

    Item 1. 
    (a)Name of Issuer

     

    SQZ Biotechnologies Company

     

    (b)Address of Issuer’s Principal Executive Offices

     

    200 Arsenal Yards Blvd, Suite 210

    Watertown, MA 02472

     

    Item 2.

     

    (a)Name of Person Filing

     

    Nanodimension II, L.P.

    Nanodimension II Management Limited

    Jonathan Nicholson

    Richard Coles

     

    (b)Address of Principal Business Office or, if none, Residence

     

    c/o Nanodimension II Management Limited

    Governor's Square, Unit 3-213-6

    23 Lime Tree Bay Ave

    Grand Cayman, Cayman Islands KY1-1302

     

    (c)Citizenship

     

    Nanodimension II, L.P. is a Cayman Islands partnership

    Nanodimension II Management Limited is a Cayman Islands corporation

    Jonathan Nicholson is a citizen of the Cayman Islands and United Kingdom

    Richard Coles is a citizen of the Cayman Islands and United Kingdom

     

    (d)Title of Class of Securities

     

    Common Stock

     

    (e)CUSIP Number

     

    78472W 10 4

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned: See the responses to Item 9 on the attached cover pages.

     

    (b)Percent of Class: See the responses to Item 11 on the attached cover pages.

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: See the responses to Item 6 on the attached cover pages.
    (ii)Shared power to vote or to direct the vote: See the responses to Item 6 on the attached cover pages.

    (iii)Sole power to dispose or to direct the disposition of: See the responses to Item 6 on the attached cover pages.
    (iv)Shared power to dispose or to direct the disposition of: See the responses to Item 6 on the attached cover pages.

     

    Page 6 of 8

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of a Group

     

    Not applicable.

     

    Item 10.Certification

     

    Not applicable.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 10, 2022

     

    Nanodimension II, L.P.  
       
    By: Nanodimension Management Limited  
    Its: General Partner  
    By: /s/ Jonathan Nicholson  
      Name: Jonathan Nicholson  
      Title: Director  

     

    Nanodimension II Management Limited

     

    By: /s/ Jonathan Nicholson  
      Name: Jonathan Nicholson  
      Title: Director  

     

    /s/ Jonathan Nicholson  
    Jonathan Nicholson  

     

    /s/ Richard Coles  
    Richard Coles  

     

    Page 8 of 8

     

    Get the next $SQZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SQZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SQZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

      Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number

      6/15/23 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

      Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e

      5/10/23 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

      A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co

      3/22/23 4:50:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vink Patrick V.J.J.

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:48:26 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Srivastava Sapna

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:47:28 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Schulman Amy W

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:46:40 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Leadership Updates

    Live Leadership Updates

    See more
    • SQZ Biotechnologies Announces Leadership Transition

      Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company's Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company's board of directors, effective October 31, 2022. Dr. Bernstein has served as the company's Chief Scientific Officer since July 2015, a

      9/6/22 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

      Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company's Chief Financial Officer, effective immediately. Mr. Zajic has served as the company's Chief Business Officer since October 2020 and brings nearly 20 years of biotechnology and capital markets experience to the role. As CFO, Mr. Zajic will continue to report to the CEO and will lead the company's finance and accounting, business development,

      7/11/22 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer

      Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer. Dr. Warren will report to the CEO and lead the company's clinical development, clinical operations, translational medicine, and regulatory affairs functions. Marshelle has tremendous experience in cell-based therapeutic development and will provide complementary expertise as we seek to rapidly advan

      5/31/22 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    SEC Filings

    See more
    • SEC Form DEFM14A filed by SQZ Biotechnologies Company

      DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/23/24 4:31:01 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PREM14A filed by SQZ Biotechnologies Company

      PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/12/24 8:57:36 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by SQZ Biotechnologies Company

      15-12G - SQZ Biotechnologies Co (0001604477) (Filer)

      1/4/24 4:15:33 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/13/24 5:13:06 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/9/24 5:10:57 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

      SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)

      2/14/23 2:25:08 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Financials

    Live finance-specific insights

    See more
    • SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

      Patient's Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic  Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflamed Phenotype with 8-Fold Increase in CD8 T Cell Tumor Infiltration and 50-Fold Increase in Tumor PD-L1 Expression Interim Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated  Company to Host Conference Call Today at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented

      12/9/21 6:10:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

      Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidate Company to Host Conference Call on December 9 at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus

      12/2/21 6:15:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care